Search
Search
Kevin Gillmann, MD, MBBS, FEBOphth, MArch, PgCert (HMS)
Show Description +
Kevin Gillmann, MD, MBBS, FEBOphth, MArch, PgCert (HMS), describes a systematic review and meta-analysis of the effect of treatment with iStent technologies (Glaukos) on the rate of visual field progression. He explains how the findings of this review suggest that early intervention with iStent technologies may be beneficial in stabilizing glaucoma progression with a favorable risk-benefit ratio.
Posted: 2/05/2024
Kevin Gillmann, MD, MBBS, FEBOphth, MArch, PgCert (HMS)
Kevin Gillmann, MD, MBBS, FEBOphth, MArch, PgCert (HMS), describes a systematic review and meta-analysis of the effect of treatment with iStent technologies (Glaukos) on the rate of visual field progression. He explains how the findings of this review suggest that early intervention with iStent technologies may be beneficial in stabilizing glaucoma progression with a favorable risk-benefit ratio.
Posted: 2/05/2024
Advancing Glaucoma Care: Embracing Early Interventional Approaches to Improve Patients’ Quality of Life
10 Years & Counting: The True Test of Time!
Prioritizing Patient Safety and the Role of Early Interventional Surgery in Glaucoma Management
Trabecular Micro-Bypass for the Treatment of Glaucoma
Long-Term Evidence With iStent® inject
iStent inject® W: A Game Changer for Clinical Practice
The Real-World Impact of iStent inject® W on Patients’ Quality of Life
Long-Term Safety and Efficacy of the iStent® Technologies
A Meta-Analysis of the Effect of iStent® Technologies on Visual Field Progression
The Role of Early Intervention in Glaucoma Management
Clinical Results From Randomized Controlled Trials
Trabecular Micro-Bypass for the Treatment of Glaucoma
Demystifying iStent inject® W for Glaucoma Surgery
Trabecular Micro-Bypass Surgery for the Management of Glaucoma
Glaucoma Disease Progression
Early Intervention Is Best for Patients With Glaucoma
About Glaukos International
Visit us online: glaukos.com
View Important Safety Information https://www.glaukos.com/en-uk/glaucoma/
References
Early Glaucoma Intervention
Florent Aptel, MD, PhD
1. Samuelson TW, Sarkisian SR Jr, Lubeck DM, et al. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results. Ophthalmology. 2019;126(6):811-821
2. Samuelson, Thomas W., et al. "Quality of life in primary open-angle glaucoma and cataract: an analysis of VFQ-25 and OSDI from the iStent inject® pivotal trial." American Journal of Ophthalmology 229 (2021): 220-229.
© 2023 Glaukos Corporation. Glaukos, iStent®, iStent inject® and iStent inject® W are registered trademarks of Glaukos Corporation. PM-EU-0261
------
Long-Term Safety and Efficacy With iStent Technologies
Imran Masood, BSc, MB ChB, MRCS(Ed) FRCOphth
1. Samuelson, Thomas W., et al. "Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results." Ophthalmology 126.6 (2019): 811-821.
2. Ahmed, Iqbal Ike K., et al. "Long-Term Endothelial Safety Profile With iStent Inject in Patients With Open-Angle Glaucoma." American journal of ophthalmology 252 (2023): 17-25.
3. Nordstrom, Beth L., et al. "Persistence and adherence with topical glaucoma therapy." American journal of ophthalmology 140.4 (2005): 598-e1.
4. Samuelson, Thomas W., et al. "Quality of life in primary open-angle glaucoma and cataract: an analysis of VFQ-25 and OSDI from the iStent inject® pivotal trial." American Journal of Ophthalmology 229 (2021): 220-229
5. Masood, I et al. Poster presented at WGC, Rome. June 2023.
© 2023 Glaukos Corporation. Glaukos, iStent®, iStent inject® and iStent inject® W are registered trademarks of Glaukos Corporation. PM-EU-0260
